NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis

Company Overview

NRx Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on the development and commercialization of repurposed and novel therapeutic candidates for diseases with high unmet medical need. Headquartered in New York, the company leverages established pharmacological compounds and patent‐protected formulations to accelerate development timelines and reduce clinical risk. Its research activities encompass neuropsychiatric disorders, inflammatory conditions and infectious disease‐related complications.

The company’s lead drug candidate, NRx‐101, is an oral fixed‐dose combination of D‐cycloserine and lurasidone in development for the treatment of bipolar depression with acute suicidal ideation or behavior. NRx‐101 has completed Phase II clinical trials and is advancing toward pivotal studies under protocols designed to meet FDA guidance for psychiatric indications. In parallel, NRx Pharmaceuticals is developing ifenprodil, an NMDA receptor antagonist licensed from Astellas Pharma, for use in respiratory distress syndromes, acute COVID-19 complications and long-term post‐viral inflammatory conditions.

NRx Pharmaceuticals operates on a model of drug repurposing and lifecycle management, in‐licensing compounds that have well‐characterized safety profiles and scaling them into new therapeutic areas. The company maintains strategic collaborations with academic medical centers and contract research organizations across North America and Europe to support its clinical programs. Its intellectual property portfolio includes composition of matter, new use and formulation patents, providing exclusivity for its lead products into the late 2030s.

The organization is led by a management team with extensive experience in pharmaceutical research, clinical operations and regulatory affairs. Senior leadership draws on backgrounds at multinational pharmaceutical companies, biotechnology startups and federal health agencies, guiding the company through clinical development milestones, regulatory interactions and strategic partnerships. NRx Pharmaceuticals continues to expand its pipeline and global footprint as it advances toward commercialization.

Key Stats

• Today's Range: $3.12 to $3.32
• 50-Day Range: $1.92 to $3.67
• 52-Week Range: $1.10 to $6.01
• Volume: 169,264 shs
• Average Volume: 422,532 shs
• Market Capitalization: $55.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.50
• Consensus Rating: Buy

NRx Pharmaceuticals Stock Analysis - MarketRank™

NRx Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 443rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

NRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

NRx Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NRx Pharmaceuticals are expected to grow in the coming year, from ($1.75) to ($0.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NRx Pharmaceuticals is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NRx Pharmaceuticals is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.58% of the float of NRx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

NRx Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NRx Pharmaceuticals has recently decreased by 24.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NRx Pharmaceuticals does not currently pay a dividend.

Dividend Growth

NRx Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.58% of the float of NRx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

NRx Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NRx Pharmaceuticals has recently decreased by 24.84%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 1.08

News Sentiment

NRx Pharmaceuticals has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for NRx Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for NRXP on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added NRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NRx Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.00% of the stock of NRx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 4.27% of the stock of NRx Pharmaceuticals is held by institutions.

NRXP Stock Analysis - Frequently Asked Questions

How have NRXP shares performed this year?

NRx Pharmaceuticals' stock was trading at $2.20 on January 1st, 2025. Since then, NRXP shares have increased by 45.9% and is now trading at $3.21.

How were NRx Pharmaceuticals' earnings last quarter?

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) posted its earnings results on Thursday, May, 15th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.06. The company had revenue of $1.14 million for the quarter, compared to analyst estimates of $1.14 million.
Read the conference call transcript.

When did NRx Pharmaceuticals' stock split?

Shares of NRx Pharmaceuticals reverse split on Tuesday, April 2nd 2024.The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of NRx Pharmaceuticals?

Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NRx Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), Meta Platforms (META), GE Aerospace (GE) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NRXP
• CIK: 1719406
• Web: www.bigrockpartners.com
• Phone: (484) 254-6134
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NRx Pharmaceuticals: $28.50
• High Price Target: $46.00
• Low Price Target: $18.00
• Potential Upside/Downside: +787.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.13 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -355.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.48) per share
• Price / Book: -2.17

Miscellaneous

• Outstanding Shares: 17,290,000
• Free Float: 14,004,000
• Market Cap: $55.50 million
• Optionable: Optionable
• Beta: 1.59